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ABSTRACT: Leishmaniasis is a neglected disease caused by parasites of 
the genus Leishmania. The disease leads to different clinical manifestations 
determined by parasite features like heterogeneity in the virulence of distinct 
species-zymodemes and host parameters such as genetic characteristics and 
immunological status. 
Visceral leishmaniasis (VL) is the most severe disease form and is 
potentially fatal if untreated. Drugs in use against VL present several 
drawbacks including high toxicity, relevant contraindications and 
complicated administration regimens. In addition, 90% of world’s VL cases 
are concentrated in poorest locations like the Indian sub-continent where 
a number of factors contribute to an ineffective disease control including 
access to medicines and its relatively expensive price and the development 
of resistant Leishmania strains, not only to the classical antimonials drugs 
but also to miltefosine, the only oral drug available. 
Therefore, the development of new drugs against VL is urgent and must 
have in consideration several aspects in order to achieve and be effective to 
most of the disease cases. Indeed, treatment outcomes vary substantially 
between different geographic regions and depend on the drug(s) used, drug 
exposure, severity of disease, host immunity, and the presence of coinfections. 
So, in order to improve the drug discovery process for anti-leishmanials 
the drug screening should involve recent clinical isolates of the L. donovani 
complex, with different susceptibility profiles to existing drugs and from 
different geographical origin. 
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Both synthetic and natural product libraries might be screened, but 
evaluation of drugs already in use by developing new formulations or 
even drug repurposing might also contribute to a faster identification of 
new candidates. Additional short-term approaches might be combinatory 
therapies, some of which have proven to be useful mainly in coinfections 
with HIV.
Other important issue is the establishment of standard techniques for 
the selection of ‘hit compounds’ and the criteria established by the Global 
Health Innovative Technology Fund represent an interesting approach: a 
given hit should present a 50% effective concentration (EC50 value) lower 
than 10μM against intracellular amastigotes of Leishmania sp. and for the 
in vivo model of VL (i.e. mouse or hamster infected with L. infantum or 
L. donovani), treatment schemes should result in 70% reduction of liver 
parasite load after up to 5 doses of 50mg/kg, orally, one or two times a day.
In the last decades, technology advances have allowed the establishment 
of High-throughput screening (HTS), a potential efficient way of identifying 
active compounds able to eliminate the parasite without affecting the host. 
However, the lack of central database capable of concentrating positive 
and negative results from different research groups and compounds tested 
also contributes to delaying the identification of potential candidates 
against Leishmania protozoa. Also by applying bioinformatic tools such 
as a systematic in silico chemogenomics strategy in combination with the 
classical approach, its expected to identify new antiparasitic compounds 
that will be available for application in the pharmaceutical industry and 
further research lines.
A relevant portion of drug prospection for neglected diseases relies on 
academic and research institution but dealing with diseases of such relevance 
worldwide must require the incorporation of Government and private 
funding for basic and clinical research projects through direct investments 
and incentives to both academia and the private sector.
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